Completed PHASE2 INTERVENTIONAL 3-arm NCT01343745

Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)

Dose Response Evaluation of CHF 1535 HFA pMDI in Asthmatic Patients Using Lung Function, Adenosine Monophosphate Bronchial Challenge and Fractional Exhaled Nitric Oxide (FENO)

Sponsor: Chiesi Farmaceutici S.p.A.

Conditions Mild Persistent Asthma

Interventions BDP/formoterol Placebo

Updated 6 times since 2017 Last updated: Oct 28, 2021 Started: Feb 29, 2008 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Mild Persistent Asthma and is currently completed. Chiesi Farmaceutici S.p.A. leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Nov 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiesi Farmaceutici S.p.A.

Data source: Chiesi Farmaceutici S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom